Abstracts tagged "collagen and fibrosis"

Abstract Number: 1054 • 2019 ACR/ARP Annual Meeting
Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis
Kristina Clark¹, Corrado Campochiaro ¹, Katherine Nevin ², Eszter Csomor ², Nicholas Galwey ², Mary Morse ², Nicolas Wisniacki ², Shaun Flint ², Voon Ong ³, Emma Derrett-Smith ¹ and Christopher Denton ⁴, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, United Kingdom, ³UCL Medical School, Royal Free Campus, London, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by autoimmunity, fibrosis and vasculopathy. There is striking heterogeneity in skin fibrosis that is likely to reflect the balance…
Abstract Number: 1848 • 2016 ACR/ARHP Annual Meeting
Adenosine A2A Receptor (A2AR) Stimulates Collagen Type III Synthesis Via β-Catenin Activation in Vitro and in Vivo
Jin Zhang¹, Gibran Shaikh², Carmen Corciulo³, Tuere Wilder³, Miguel Perez-Aso¹, Aranzazu Mediero¹ and Bruce Cronstein¹, ¹Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, NYU School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Fibrosis of skin and other organs is a hallmark of Scleroderma. We and others have previously reported that A2AR plays a role in skin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].